THC BioMed Releases First Quarter Results

Published: December 2, 2021

THC BioMed Releases First Quarter Results

THC BioMed Intl Ltd. reported its financial results for the three months ended October 31, 2021.

Q1 HIGHLIGHTS

  • Produced a gross margin profit after fair value adjustments of $711,761 and net income of $25,006
  • Sales revenue increased 83% period to period
  • Sales of edibles in Q1 made up 21.3% of total sales
  • Facility buildout completed
  • Received a Notice of Allowance from the Canadian Patent and Trademark Office regarding its patent application for the invention of a Contrast Illuminated Tamper Resistant Plant Shipping Container, or the Clone Shipper unit. The Notice of Application is not a grant of patent rights at this time but a notice from the Examiner that the Application is being allowed.

HIGHLIGHTS SUBSEQUENT TO OCTOBER 31, 2021

  • On November 1, 2021, the Company entered into a lease for an additional unit at the facility on Acland Road in Kelowna, British Columbia. The lease is for a five year term expiring October 31, 2026. The monthly lease payment is $2,500 plus costs of $726 excluding the Goods and Services Tax. This unit will be used for administration

MANAGEMENT COMMENT

“We are pleased to report net income for the quarter. This reflects the hard work to streamline production, especially regarding our edible products,” said THC BioMed President and CEO, John Miller. “Going forward, we intend on concentrating on the edibles market and specifically our THC Kiss Beverage Shot, THC Kiss Gummies and THC Kiss Biscuits which will continue to improve our gross margin and subsequent bottom line.”

SUMMARY OF QUARTERLY RESULTS

Quarter Ended

Revenue

Net
Income (Loss)

Income (Loss)
Per Share

Q1/2022

October 31, 2021

$

1,136,796

$

25,006

$

Q4/2021

July 31, 2021

$

1,020,804

$

(1,426,064)

$

(0.01)

Q3/2021

April 30, 2021

$

1,109,503

$

(1,319,503)

$

(0.01)

Q2/2021

January 31, 2021

$

1,021,989

$

(2,921,510)

$

(0.02)

Q1/2021

October 31, 2020

$

622,025

$

(692,177)

$

Q4/2020

July 31, 2020

$

990,940

$

(642,989)

$

(0.01)

Q3/2020

April 30, 2020

$

896,104

$

(295,717)

$

Q2/2020

January 31, 2020

$

1,246,625

$

88,191

$

STATEMENT OF NET AND COMPREHENSIVE LOSS SUMMARY

For the three months ended

October 31
2021

October 31
2020

Revenue

$

1,136,796

$

622,025

Production costs

(1,069,111)

(729,379)

Gross profit before fair value adjustments

67,685

(107,354)

Net change in fair value of biological assets

644,076

20,353

Gross margin

711,761

(87,001)

Total expenses

686,755

605,176

Net and comprehensive income (loss) for the period

$

25,006

$

(692,177)

STATEMENT OF FINANCIAL POSITION SUMMARY

October 31

July 31

As at

2021

2021

Current assets

$

5,266,701

$

4,271,435

Total assets

$

18,250,253

$

17,396,441

Current liabilities

$

5,035,152

$

5,968,492

Total liabilities

$

8,308,698

$

7,613,032

Working capital

$

231,549

$

(1,697,057)

Accumulated deficit

$

30,482,330

$

30,551,021

CASH FLOW STATEMENT SUMMARY

For the three months ended

October 31
2021

October 31
2021

Net and comprehensive income (loss) for the period

$

25,006

$

(692,177)

Cash, end of the period

$

377,096

$

232,091

NON-IFRS EARNINGS MEASURE

For the three months ended

October 31
2021

October 31
2020

Net and comprehensiveincome ( loss) for the period

$

25,006

$

(692,177)

Add back

Interest

103,585

51,504

Depreciation and amortization

219,852

241,882

EBITDA from continuing operations

348,443

(398,791)

Share-based compensation

94,204

34,620

Net changes in fair value of biological assets

(711,761)

87,001

Adjusted EBITDA

$

(269,114)

$

(277,170)

The Company defines Adjusted EBITDA as net income (loss) excluding fair value changes on growth of biological assets, realized fair value changes on inventory sold or impaired, amortization of property plant and equipment & intangible assets, share based payments, finance expense, loss on disposal of property plant and equipment, unrealized gains or losses on investments and income taxes. This non-IFRS measure is defined in the Company’s MD&A for the three months ended October 31, 2021 and 2020.

All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. This press release is intended to be read in conjunction with the Company’s Condensed Interim Consolidated Financial Statements and Management’s Discussion & Analysis for the three months ended October 31, 2021 and 2020, which has been filed on SEDAR (www.sedar.com).

ABOUT THC Biomed
THC BioMed is one of Canada’s oldest active licensed cannabis companies. It was first licensed to deal with cannabis in 2013 under a Health Canada Section 56 exemption under the Controlled Drugs and Substances Act and has been a Licensed Producer under the current regime since 2016. It is a small batch producer and aims to be a leader in the beverage and edible space. THC BioMed is a Licensed Producer of medical and recreational cannabis under the Cannabis Act. It is licensed to cultivate and sell dried, extract, edible, and topical cannabis. The Company is on the leading edge of scientific research and the development of products and services related to the cannabis industry. THC BioMed is well-positioned to be in the forefront of this rapidly growing industry. Please visit our website for a more detailed description of our business and services available. www.thcbiomed.com

Recent News

View All News Items

Latest Article

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

How Database Integrations Can Improve Every Step in Your Cannabis Supply Chain Labeling

At any step in the cannabis supply chain, your labeling system should allow for full control and traceability, from seed to sale. Implementing lean principles and labeling best practices across the cannabis supply chain can help you streamline your seed-to-sale labeling process and help you gain control.

Click below to read the full blog and learn how to reduce waste, cut costs, and gain efficiency with cannabis labeling: https://bit.ly/2KwZ5IQ

Read Article